| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4023637 | Journal Français d'Ophtalmologie | 2015 | 9 Pages |
Abstract
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN®, which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN® in DME, are discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
G. Soubrane, F. Behar-Cohen,